Compare AbbVie Inc (ABBV) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Marathon Petroleum Corp — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Marathon Petroleum Corp trades at $275.51 (market cap $77.75B). The key difference: AbbVie Inc is far larger — about 5.8× Marathon Petroleum Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MPC | |
|---|---|---|
Market Cap | $449.91B | $77.75B |
Sector | Health | Energy |
52-Week High | $261.07 | $268.99 |
52-Week Low | $184.85 | $158.59 |
Enterprise Value | $513.38B | $109.93B |
Dividend Yield | 2.72% | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Marathon Petroleum (MPC) trades at $266.33, showing minimal daily movement (-0.01%) but maintaining strong momentum with a 52% gain over the past six months. The stock demonstrates robust profitability with ROE of 27.92% and net income margin of 3.42%, supported by favorable refining margins from global supply disruptions. Recent earnings show mixed performance with Q3 2025 missing estimates but Q1 2026 beating expectations by 123%.
MPC presents a compelling investment case with attractive valuation (P/E 17.71, P/S 0.6) and strong analyst support (76% buy ratings). However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% warrant caution. The upcoming Q2 2026 earnings on August 4th will be critical for validating the current bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
